Compare Owens & Minor, Inc. with Similar Stocks
Dashboard
1
Weak Long Term Fundamental Strength with a 20.30% CAGR growth in Operating Profits over the last 5 years
- Low ability to service debt as the company has a high Debt to EBITDA ratio of 4.13 times
- The company has been able to generate a Return on Capital Employed (avg) of 11.05% signifying low profitability per unit of total capital (equity and debt)
2
Negative results in Jun 25
3
Risky -
4
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
USD 185 Million (Micro Cap)
1.00
NA
0.00%
-3.84
-33.06%
-0.40
Revenue and Profits:
Net Sales:
709 Million
(Quarterly Results - Dec 2025)
Net Profit:
-9 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-23.62%
0%
-23.62%
6 Months
-60.8%
0%
-60.8%
1 Year
-77.67%
0%
-77.67%
2 Years
-92.0%
0%
-92.0%
3 Years
-83.25%
0%
-83.25%
4 Years
-95.22%
0%
-95.22%
5 Years
-94.01%
0%
-94.01%
Owens & Minor, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-11.06%
EBIT Growth (5y)
-5.52%
EBIT to Interest (avg)
3.42
Debt to EBITDA (avg)
4.13
Net Debt to Equity (avg)
3.31
Sales to Capital Employed (avg)
3.79
Tax Ratio
0.13%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
11.05%
ROE (avg)
16.41%
Valuation key factors
Factor
Value
P/E Ratio
1
Industry P/E
Price to Book Value
-0.40
EV to EBIT
10.83
EV to EBITDA
4.55
EV to Capital Employed
1.49
EV to Sales
0.41
PEG Ratio
0.02
Dividend Yield
NA
ROCE (Latest)
13.80%
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
No Trend
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 68 Schemes (66.18%)
Foreign Institutions
Held by 97 Foreign Institutions (8.81%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
709.00
697.30
1.68%
Operating Profit (PBDIT) excl Other Income
86.60
93.20
-7.08%
Interest
28.70
30.00
-4.33%
Exceptional Items
-1.10
-2.70
59.26%
Consolidate Net Profit
-9.40
-5.60
-67.86%
Operating Profit Margin (Excl OI)
31.10%
41.80%
-1.07%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is 1.68% vs 2.26% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is -67.86% vs 93.32% in Sep 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
2,762.00
2,680.10
3.06%
Operating Profit (PBDIT) excl Other Income
364.70
356.40
2.33%
Interest
129.20
115.40
11.96%
Exceptional Items
-122.70
-392.90
68.77%
Consolidate Net Profit
-102.70
-350.70
70.72%
Operating Profit Margin (Excl OI)
54.40%
65.40%
-1.10%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 3.06% vs -74.07% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 70.72% vs -749.15% in Dec 2024
About Owens & Minor, Inc. 
Owens & Minor, Inc.
Pharmaceuticals & Biotechnology
Owens & Minor, Inc. is a healthcare solutions company with integrated technologies, products and services. The Company operates through two segments: Global Solutions and Global Products. Global Solutions segment includes its United States distribution, outsourced logistics and value-added services business. Global Products manufactures and sources medical surgical products through its production and kitting operations. Global Solutions segment offers a portfolio of products and services to healthcare providers and manufacturers. Its portfolio of medical and surgical supplies includes products purchased from manufacturers and its own proprietary products. Global Products segment provides medical supplies and solutions for the prevention of healthcare-associated infections across the acute and alternate site channels. Its manufacturing facilities are located in the United States, Thailand, Honduras, Mexico and Ireland.
Company Coordinates 
Company Details
9120 LOCKWOOD BLVD , MECHANICSVILLE VA : 23116
Registrar Details






